13 september 2022: ESMO 2022

Afgelopen week was er ESMO 2022. Hier een aantal aanbevolen abstracten door vooraanstaande oncologen gerelateerd aan blaaskanker, urineleiderkanker en nierkanker

De aanbevolen abstracten staan onder elkaar in dit artikel. Als u naar ESMO 2022 gaat kunt u via de nummers van de abstracten deze vinden.

Aanbevoilen abstracten door Petros Grivas MD, PhD 

Saturday, September 10, 2022
10:15–10:45 CEST; Proffered Paper Session 1
GU Tumours, Non-Prostate

LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection A Bex

LBA67 Phase III RandOmized Study Comparing PErioperative Nivolumab (nivo) versus Observation in Patients (Pts) with Renal Cell Carcinoma (RCC) Undergoing Nephrectomy (PROSPER, ECOG-ACRIN EA8143), a National Clinical Trials Network trial. M Allaf

LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC). TB Powles

1735O PD-L1 expression on immune cells by SP142 co-localises with dendritic cells and is associated with improved overall survival (OS) with atezolizumab in patients with untreated metastatic urothelial cancer (mUC). EG Pulido

Sunday, September 11, 2022
16:30–18:15 CEST; Proffered Paper Session
Presidential Symposium II

LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: results from the randomized, phase 3 CheckMate 914 trial. RJ Motzer

Monday, September 12, 2022
14:45–16:15 CEST; Proffered Paper Session 2
GU Tumours, Non-Prostate

LBA68 Bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) compared to the investigator’s choice of Sunitinib or Cabozantinib in previously untreated advanced renal cell carcinoma (RCC): Results from a Phase 3 randomized study (PIVOT-09). N Tannir

LBA73 Study EV-103 Cohort K: Antitumor activity of enfortumab vedotin (EV) monotherapy or in combination with pembrolizumab (P) in previously untreated cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (la/mUC). JE Rosenberg

1447O Phase II study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC): Cohort 1 of LITESPARK-003. J Merchan

1448O Phase II KEYNOTE-B61 study of pembrolizumab (Pembro) + lenvatinib (Lenva) as first-line treatment for non-clear cell renal cell carcinoma (nccRCC). L Albiges

Monday, September 12, 2022
16:30–18:15 CEST; Proffered Paper Session
Presidential Symposium III

LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313). TK Choueir

Plaats een reactie ...

Reageer op "ESMO 2022: aanbevolen abstracten gerelateerd aan blaaskanker en nierkanker door vooraanstaande oncologen. copy 1"

Gerelateerde artikelen

Gerelateerde artikelen

Waaraan moet een ziekenhuis >> Overzicht van belangrijke >> ESMO 2022: aanbevolen abstracten >> ASCO 2023. Aanbevolen abstracten >> Algemeen: Verhoogde bloedwaarden >> Chemotherapie met gemcitabine >> HIFU - High Focused Ultra >> Immuuntherapie bij nierkanker, >> Interferon Alpha als aanvullende >> Nexavar(R) (sorafenib tosylate) >>